The Unclear Role of Methotrexate in the Treatment of Diffuse Large-Cell Lymphoma

References

• DeVita V T, Jr, Canellos G P, Chabner B, et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Results with combination chemotherapy. Lancet 1975; 1: 248–250
   PubMed Web of Science ®Google Scholar
• Nissen N I, Pajak T, Glidewell O, et al. Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B. Cancer Treat Rep 1977; 61: 1097
   PubMedGoogle Scholar
• McKelvey E M, Gottlieb J A, Wilson H E, et al. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484–1493
   PubMed Web of Science ®Google Scholar
• Jones S E, Grozea P N, Metz E N, et al. Superiority of Adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma. A Southwest Oncology Group study. Cancer 1979; 43: 417–425
   PubMed Web of Science ®Google Scholar
• Rodriquez V, Cabanillas F, Burgess M, et al. Combination chemotherapy (“CHOP-Bleo”) in advanced (non-Hodgkin) malignant lymphoma. Blood 1977; 49: 325–333
   PubMed Web of Science ®Google Scholar
• Young R C, Howser D M, Anderson T, et al. Central nervous system complications of non-Hodgkin's lymphoma. The potential role of prophylactic therapy. Am J Med 1979; 66: 435–443
   PubMed Web of Science ®Google Scholar
• Sweet D L, Golomb H M, Ultmann J E, et al. Cyclophosphamide, vincristine, methotrexate with leucovorin rescue and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Intern Med 1980; 92: 785–790
   PubMed Web of Science ®Google Scholar
• Litam J P, Cabanillas F, Smith T L, et al. Central nervous system relapse in malignant lymphomas: Risk factors and implications for prophylaxis. Blood 1979; 54: 1249–1257
   PubMed Web of Science ®Google Scholar
• Todd M, Cadman E, Bertino J, et al. A followup of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma. J Clin Oncol 1984; 2: 986–993
   PubMed Web of Science ®Google Scholar
• Livingston R B, Carter S K. Single Agents in Cancer Chemotherapy. GI/Plenum, New York 1970; 145
   Google Scholar
• Canellos G P, Skarin A T, Rosenthal D S, et al. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. Cancer Treat Rep 1981; 65(suppl 1)125–129
   PubMedGoogle Scholar
• Frei E, III, Blum R H, Pitman S W, et al. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 1980; 68: 370–376
   PubMed Web of Science ®Google Scholar
• Skarin A T, Canellos G P, Rosenthal D S, et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol 1983; 1: 91–98
   PubMed Web of Science ®Google Scholar
• Skarin A, Canellos G, Rosenthal D S, et al. Moderate dose methotrexate (M) combined with Bleomycin (B), Adriamycin (A), cyclophosphamide (C), Oncovin (O) and dexamethasone (D), m-BACOD in advanced diffuse histiocytic lymphoma (DHL). AACR/ACSO Proc 1980; 21: 463, Abstract C-861
   Google Scholar
• Fisher R I, DeVita V T, Jr, Hubbard S M, et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of PtoMACE and MOPP chemotherapy. Ann Intern Med 1983; 98: 304–309
   PubMed Web of Science ®Google Scholar
• Sparling H J, Jr, Adams R D, Parker F, Jr. Involvement of the nervous system by malignant lymphoma. Medicine (Baltimore) 1947; 26: 285–332
   PubMed Web of Science ®Google Scholar
• Mullins G M, Flynn J P, El-Mahdi A M, et al. Malignant lymphoma of the spinal epidural space. Ann Intern Med 1971; 74: 416–423
   PubMed Web of Science ®Google Scholar
• Law I P, Dick F R, Blom J, et al. Involvement of the central nervous system in non-Hodgkin's lymphoma. Cancer 1975; 36: 225–231
   PubMed Web of Science ®Google Scholar
• Bunn P A, Jr, Schein P S, Banks P M, et al. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: Leukemia revisited. Blood 1976; 47: 3–10
   PubMed Web of Science ®Google Scholar
• Mackintosh F R, Colby T V, Podolsky W J, et al. Central nervous system involvement in non-Hodgkin's lymphoma: An analysis of 105 cases. Cancer 1982; 49: 586–595
   PubMed Web of Science ®Google Scholar
• Armitage J O, Cander M P, Leimert J T, et al. Advanced histiocytic lymphoma treated with cyclophosphamide doxorubicin, vincristine and prednisone (CHOP) without maintenance therapy. Cancer Treat Rep 1980; 64: 649–654
   PubMedGoogle Scholar
• Coltman C A, Jr, Luce J K, McKelvey E M, et al. Chemotherapy of non-Hodgkin's lymphoma: 10 years' experience in the Southwest Oncology Group. Cancer Treat Rep 1977; 61: 1067–1078
   PubMedGoogle Scholar
• Klimo P, Connors J M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Herman T S, Hammond N, Jones S E, et al. Involvement of the central nervous system by non-Hodgkin's lymphoma. The Southwest Oncology Group experience. Cancer 1979; 43: 390–397
   PubMed Web of Science ®Google Scholar
• Shapiro W R, Young D F, Mehta B M. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 1975; 293: 161–166
   PubMed Web of Science ®Google Scholar
• Hryniuk W M, Bertino, Jr. Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical—biochemical correlates. J Clin Invest 1969; 48: 2140–2155
   PubMed Web of Science ®Google Scholar
• Tattersall M HN, Parker L M, Pitman S W, et al. Clinical pharmacology of high-dose methotrexate (NSC-740). Cancer Chemother Rep 1975; 6: 25–29
   Google Scholar
• Cadman E, Farber L, Berd D, et al. Combination therapy for diffuse histiocytic lymphoma that includes antimetabolites. Cancer Treat Rep 1977; 61: 1109–1116
   PubMedGoogle Scholar
• Fisher R I, DeVita V T, Jr, Hubbard S M, et al. Randomized trial of ProMACE-MOPP vs. ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. AACR/ASCO Proc 1984; 242, abstract C-945
   Google Scholar
• Schein P S, DeVita V T, Jr, Hubbard S, et al. Bleomycin, Adriamycin, cyclophosphamide, vincristine and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. Ann Intern Med 1976; 85: 417–422
   PubMed Web of Science ®Google Scholar